Video
Video course abdominal ultrasound
Patient in a standing position
Author: Prof. Dr. Christoph F. Dietrich, Caritas Krankenhaus Bad Mergentheim.
© 2015 Falk Foundation e.V., Freiburg. All rights reserved.
Please switch on your loudspeakers!
Link to Falk Mediacenter:
http://media.falkfoundation.de/index.php?id=133&L=1
Link to the video directly:
http://media.drfalkpharma.de/fileadmin/media/18_Liver_Patient_in_a_standing_position_ENG.mp4
Preview images:
580 x 325 pixels (with arrow)
http://www.drfalkpharma.de/fileadmin/media/newsletter/Logos/Sono_Clip18_580P.jpg
580 x 325 pixels (without arrow)
http://www.drfalkpharma.de/fileadmin/media/newsletter/Logos/Sono_Clip18_580.jpg
Latest research in brief:
Description field (to be displayed at the end of the structural element):
Bowel
http://www.drfalkpharma.de/fileadmin/media/logos_falk/abstracts/Falk-Darm.png
Text:
Fréling E et al, Am J Gastroenterol. 2015;110(8):1186–96
Dermatological complications due to anti-TNF therapy in IBD: Although psoriasiform lesions and infections occur in approx. 20% of patients, therapy can be continued in the majority of patients.
Link:
http://www.drfalkpharma.de/index.php?L=1&id=20374#29328
Text:
van Heijningen EM et al, Gut. 2015;64(10):1584–92
Adherence to surveillance guidelines after removal of colorectal adenomas: Only less than 25% of patients in a huge Dutch patient cohort received appropriate surveillance according to guidelines.
Link:
http://www.drfalkpharma.de/index.php?L=1&id=20374#c29330
Text:
Aziz I et al, Clin Gastroenterol Hepatol. 2015;13(9):1650–5.e2
Important differential diagnosis for diarrhea-predominant irritable bowel syndrome (IBS-D): 25% of patients with IBS-D according to Rome III criteria have idiopathic bile acid diarrhea which should therefore be excluded before diagnosing IBS-D.
Link:
http://www.drfalkpharma.de/index.php?L=1&id=20374#c29331
Liver
Biliary Tracts
http://www.drfalkpharma.de/fileadmin/media/logos_falk/abstracts/Falk-Leber.png
Text:
Charlton M et al, Gastroenterology. 2015;149(3):649–59
Hepatitis C: Ledipasvir and sofosbuvir plus ribavirin for 12 weeks lead to high rates of viral clearance even in patients with advanced liver cirrhosis. This therapy is very efficient even in patients with decompensated liver cirrhosis before or after liver transplantation.
Link:
http://www.drfalkpharma.de/index.php?L=1&id=20374#c29332
Text:
Sauerbruch T et al, Gastroenterology. 2015;149(3):660–8.e1
Liver cirrhosis: Prevention of rebleeding from esophageal varices by a small-diameter, covered transjugular intrahepatic portosystemic shunt (TIPS) is more effective than drug therapy. Treatment by TIPS did however not increase survival time or quality of life.
Link:
http://www.drfalkpharma.de/index.php?L=1&id=20374#c29333
Text:
Kushner T et al, J Hepatol. 2015;63(3):586–92
Hepatitis delta: Testing rates for hepatitis delta in chronic hepatitis B patients in the United States are inappropriately low (8.5%). All patients with chronic hepatitis B should be tested at least once for co-infection with hepatitis D virus.
Link:
http://www.drfalkpharma.de/index.php?L=1&id=20374#c29334
Oesophagus
Stomach
Duodenum
http://www.drfalkpharma.de/fileadmin/media/logos_falk/abstracts/Falk-Magen.png
Text:
Small AJ et al, Gastroenterology. 2015;149(3):567–76.e3
Therapy of Barrett’s esophagus with confirmed low-grade intraepithelial neoplasia: Radiofrequency ablation is associated with decreased neoplastic progression.
Link:
http://www.drfalkpharma.de/index.php?L=1&id=20374#c29335
Text:
Carroccio A et al, Gastroenterology. 2015;149(3):596–603.e1
Non-celiac wheat sensitivity: High proportions of patients have autoimmune disease and antinuclear antibodies.
Link:
http://www.drfalkpharma.de/index.php?L=1&id=20374#c29336
Text:
Chan EW et al, Gastroenterology. 2015;149(3):586–95.e3
Gastrointestinal bleeding related to dabigatran: PPI and H2-antagonists are associated with a reduced risk of upper gastrointestinal bleeding, in particular in patients with prior history of peptic ulcer disease or previous bleeding episodes.
Link:
http://www.drfalkpharma.de/index.php?L=1&id=20374#c29337
Pancreas
http://www.drfalkpharma.de/fileadmin/media/logos_falk/abstracts/Falk-Pankreas.png
Text:
Wu BU et al, Am J Gastroenterol. 2015;110(8):1233–9
Protective effects of statins in pancreatic carcinoma: Moderate- or high-dose therapy with simvastatin at baseline is associated with improved overall and disease-free survival.
Link:
http://www.drfalkpharma.de/index.php?L=1&id=20374#c29338
Falk Symposia
Falk Symposium 199
VIII Falk GASTRO-CONFERENCE (Part I)
Highlights from Hepatology 2015: From Chronic Hepatitis to Hepatocellular Carcinoma
Bild:
http://www.drfalkpharma.de/fileadmin/media/newsletter/symposium.gif
Text:
October 14 – 15, 2015, Freiburg, Germany
Konzerthaus Freiburg, Konrad-Adenauer-Platz 1, 79098 Freiburg, Germany
Link1:
Link2:
Link für Online-Anmeldung:
http://events.drfalkpharma.de/index.php?id=105&L=1
Falk Symposium 200
VIII Falk GASTRO-CONFERENCE (Part II)
Therapeutic Strategies in Diseases of the Digestive Tract – 2015 and Beyond
Bild:
http://www.drfalkpharma.de/fileadmin/media/newsletter/symposium.gif
Text:
October 16 – 17, 2015, Freiburg, Germany
Konzerthaus Freiburg, Konrad-Adenauer-Platz 1, 79098 Freiburg, Germany
Link1:
Link2:
Link für Online-Anmeldung:
http://events.drfalkpharma.de/index.php?id=105&L=1
Falk Workshop
Workshop on Gastrointestinal GVHD
Bild:
http://www.drfalkpharma.de/fileadmin/media/newsletter/falk_workshop.gif
Text:
November 13 – 14, 2015, Regensburg, Germany
University Hospital Regensburg, Franz-Josef-Strauss-Allee 11, 93053 Regensburg, Germany
Link1:
Link2:
Link für Online-Anmeldung:
http://events.drfalkpharma.de/index.php?id=109&L=1
Workshop
Communications and System Relevance in Liver Damage and Regeneration
Bild:
http://www.drfalkpharma.de/fileadmin/media/newsletter/falk_workshop.gif
Text:
January 21 – 22, 2016, Düsseldorf, Germany
Building 23.01, Hörsaal 3D, Heinrich-Heine University, Universitätsstr. 1, 40225 Düsseldorf, Germany
Link1:
Link2:
Link für Online-Anmeldung:
http://events.drfalkpharma.de/index.php?id=42&L=1
Symposium 201
Gut-Liver Interactions: From IBD to NASH
Bild:
http://www.drfalkpharma.de/fileadmin/media/newsletter/symposium.gif
Text:
March 11 – 12, 2016, Innsbruck, Austria
Congress Innsbruck, Rennweg 3, 6020 Innsbruck, Austria
Link1:
Link2:
Link für Online-Anmeldung:
http://events.drfalkpharma.de/index.php?id=205&L=1
Current Falk literature:
NEW
Falk Symposium report
Falk Symposium 196
Critical Evaluation of Current Concepts and Moving to New Horizons in the Management of IBD
Frankfurt (Germany), March 6 – 7, 2015
(36 pages)
FSR196e
Picture:
http://www.drfalkpharma.de/fileadmin/media/Falk_Veranstaltungen/Falk_Symposium_Report/FSR196e.jpg
PDF:
Order by email (Please replace text by your email address):